The Effect of Respiratory Rehabilitation on Systemic Inflammation in COPD - Myokine Action and Muscle-Bone Crosstalk
- Conditions
- Chronic obstructive pulmonary disease
- Registration Number
- JPRN-UMIN000050820
- Lead Sponsor
- Gunma University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Not provided
1. Patients who need assistance from others when moving indoors, and who need a walking aid other than a cane or drip stand when walking. 2. Patients who have had a short-term exacerbation within the past 4 weeks of the study entry, according to the GOLD definition. 3. Patients with blood sputum of unknown cause. 4. Patients with angina pectoris, unstable cardiovascular disease, or aortic aneurysm. 5. Patients diagnosed with myocardial infarction or pulmonary embolism 6. Have undergone eye surgery (cataract or glaucoma) within the past 4 weeks from the date of study entry. 7. Underwent thoracic or abdominal surgery within the past 4 weeks from the date of study entry. 8. Those who are unable to give explanation and consent due to cognitive functional aspects or psychiatric symptoms. 9. Those who need anti-inflammatory drugs (oral steroids, NSAIDs, etc.) as treatment. 10. Patients who cannot discontinue active vitamin D3 preparations for the treatment of osteoporosis. 11. Regular use of vitamins, protein drinks, amino acids, or other beverages or supplements in the past month. 12. Patients with chronic kidney disease whose urinalysis shows proteinuria of 0.15 g/gcr or more, or whose eGFR is less than 60 mL/min/1.73 m2, or both have persisted for more than 3 months. Patients with chronic kidney disease or other renal diseases. 13. Patients with a diagnosis of liver dysfunction such as acute hepatitis, chronic hepatitis, fatty liver, cirrhosis, etc. 14. Patients who have regularly exercised for at least 60 minutes every week for at least 3 METs of breathless and sweaty exercise, such as running or water exercise, during the past 3 months.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoints of this study will be the difference in blood levels of serum Irisin, and serum 25(OH)D levels at 1) pre-exercise intervention, 2) post-short-term exercise intervention, and 3) post-long-term exercise intervention. Serum Irisin and serum 25(OH)D from the three time periods will be analyzed by two-way ANOVA to confirm the interaction and perform the corresponding multiple comparison tests. A two-sided p-value of 0.05 or less is considered statistically significant in the statistical test.
- Secondary Outcome Measures
Name Time Method